SBI Term Loan: RLLR: 8.15 | 7.25% - 8.55%
Canara Bank: RLLR: 8 | 7.15% - 9.85%
ICICI Bank: RLLR: -- | 8.5% - 9.65%
Punjab & Sind Bank: RLLR: 7.3 | 7.35% - 10.75%
Bank of Baroda: RLLR: 7.9 | 7.2% - 8.95%
Federal Bank: RLLR: -- | 7.35% - 9.6%
IndusInd Bank: RLLR: -- | 7.6% - 10%
Bank of Maharashtra: RLLR: 8.05 | 7% - 9.15%
Yes Bank: RLLR: -- | 7.4% - 10.54%
Karur Vysya Bank: RLLR: 8.8 | 8.5% - 10.65%
HDFC Bank: RLLR: -- | 7.75% - 13.2%
Axis Bank: RLLR: -- | 8% - 9.1%
IDBI Bank: RLLR: -- | 7.4% - 10%

Lonza to acquire five US manufacturing sites from Merck KGaA

#International News#Industrial#United States of America
Synopsis

Swiss contract development and manufacturing organisation Lonza has agreed to acquire five manufacturing sites in the United States from German pharmaceutical and chemicals group Merck KGaA. The transaction is valued in the low- to mid-triple-digit million Swiss franc range, although an exact figure has not been disclosed. The acquisition will add five US facilities to Lonza’s manufacturing network. Details of the sites, their production capabilities and the expected completion date were not provided in the companies’ announcement.

Swiss contract development and manufacturing organisation Lonza has agreed to acquire five manufacturing sites in the United States from Merck KGaA, the companies announced on November 3. 
Lonza said the transaction is valued in the low- to mid-triple-digit million Swiss franc range. However, neither company disclosed the exact purchase price or provided a breakdown of the valuation across the five facilities. 
The acquisition covers five manufacturing locations in the US. The companies have not identified the individual sites or specified the types of products currently manufactured at these facilities. Details of their production capacities, workforce, infrastructure and operational status were also not included in the announcement. 
The transaction will expand Lonza’s US manufacturing footprint once completed. The company operates across contract development and manufacturing services, supporting pharmaceutical and biotechnology businesses in developing and producing medicines. Its manufacturing network spans multiple regions, with facilities serving different stages of the pharmaceutical production process. 
For Merck KGaA, the agreement involves the transfer of five US manufacturing sites to Lonza. The German group operates across healthcare, life science and electronics businesses, with its life science division supplying products and services used in pharmaceutical research, development and manufacturing. However, the companies have not specified which business activities or product categories are associated with the facilities covered by this transaction. 
The announcement also did not clarify whether the sites will continue serving existing customers under Lonza’s ownership or whether their operations will be integrated into other parts of its manufacturing network. Information on employee transfers, customer agreements and any planned operational changes remains undisclosed. 
The acquisition value places the transaction in the low- to mid-triple-digit million Swiss franc range, but the absence of a precise figure limits further assessment of its financial scale. Lonza has also not disclosed whether the purchase will be financed through internal resources, borrowings or another arrangement. 
The companies did not announce a completion date or provide details of regulatory approvals and other closing conditions. Further information on the facilities and the planned transition is expected to clarify how the acquisition will affect Lonza’s manufacturing capacity and Merck KGaA’s US operations. 
Source: Reuters

Discussion

Have something to say? Post your comment